China Nepstar - Melting Down?

Summary

  • Stock blasted after Q3, down 25%, hitting a fresh 52-week low.
  • Margin pressure in Q3 could abate in Q4, a seasonally strong quarter.
  • What does the price now say about the business fundamentals?

China Nepstar (NPD, profile) was slammed lower in trading yesterday, shedding about 11% on above average volume. Over the past two days, the stock shed about 13%, making it one of the worst performers in the universe of US-listed China stocks.

Although there were no major news items to point the finger to, there was broad selling in China's domestic stock markets which could have led to Nepstar falling in sympathy. Shanghai-listed No. 1 Pharamacy (600833) dropped nearly 8% on Tuesday, and other drug and pharma names were also lower on the day. Investors were selling across all sectors of the market on Tuesday, and didn't leave drugs stores or related pharma names untouched.

Nepstar has been trading lower after an underwhelming Q3 (the company reported late November) which although included revenue growth, was coupled with margin weakness. Tuesday's drop brought the post-Q3 slide to a total loss of nearly 25%.

At the close of trade yesterday, China Nepstar's market cap was about 131 million USD, or about 64,000 USD per store. Considering that it takes approximately 70,000 USD to open a new store (not including inventory of over 30,000 USD), the stock was trading below the replacement value of the existing store network. (For those interested in the math, replicating the company's 2,050 store chain would take over 140 million USD, which does not include inventory or any of the necessary overhead expenditures.)

By trading so cheaply, the stock price seems to imply relatively heavy operating losses, but is that reasonable?

The fourth quarter is seasonally strong for drug stores in China, owing in part to the winter cold and flu season. So far in FY2014, Nepstar has been delivering higher revenues based on strong comparable store sales, which speaks well of the quality of revenue growth (more organic vs. opening new stores), a trend which

This article was written by

Official account for ChinaStockResearch.com Several years experience as an analyst in the hedge fund world. Investment knowledge includes long/short equities, credit, macro, arbitrage, distressed debt, and special situations. Previous research publication experience includes Japanese small cap research distributed to institutional investors. Education credentials include BS in Computer Science, MBA in Finance, and CFA Charter. Follow on Twitter @ChinaStockRsrch Follow on StockTwits @ChinaStockResearch

Analyst’s Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

More on NPD-DEFUNCT-9085

Related Stocks

SymbolLast Price% Chg
NPD
--